Alnylam Pharmaceuticals Announces Closing of Public Offering of Common Stock & Full Exercise of Underwriters’ Option to Pur...
November 16 2017 - 4:00PM
Business Wire
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi
therapeutics company, today announced the closing of its previously
announced underwritten registered public offering of 6,440,000
shares of its common stock, including 840,000 shares sold pursuant
to the underwriters’ full exercise of their option to purchase
additional shares, at a public offering price of $125.00 per share.
The aggregate gross proceeds to Alnylam from the offering, before
deducting the underwriting discounts and commissions and other
estimated offering expenses, are expected to be $805 million.
Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and
Barclays Capital Inc. acted as joint book-running managers for the
offering. Credit Suisse acted as lead manager for the offering and
Piper Jaffray & Co., JMP Securities, Needham & Company,
Chardan and B. Riley FBR acted as co-managers for the offering.
Alnylam intends to use the net proceeds from this offering for
general corporate purposes, including clinical trial costs and
other research and development expenses, continued growth of its
manufacturing, quality, commercial and medical affairs capabilities
to support its transition toward a commercial-stage
biopharmaceutical company, the anticipated commercial launches of
patisiran, givosiran and fitusiran across several continents,
assuming favorable regulatory reviews, the expected commercial
expansion beyond the United States, Canada and Western Europe for
givosiran and other potential future products, the potential
expansion of patisiran commercialization efforts in mixed phenotype
populations, assuming consistent product labelling, potential
repayment of outstanding indebtedness, potential acquisitions,
investments or licenses in businesses, products or technologies
that are complementary to its own, working capital, capital
expenditures and general and administrative expenses.
The securities described above were offered by Alnylam pursuant
to an automatically effective shelf registration statement that
Alnylam previously filed with the Securities and Exchange
Commission (SEC).
A registration statement (including a base prospectus and a
prospectus supplement) relating to these securities has been filed
with the SEC and has become effective. Before you invest,
you should read these and other documents Alnylam has filed with
the SEC for more complete information about Alnylam and
this offering. You may get these documents for free by visiting
EDGAR on the SEC website at www.sec.gov.
The offering was made only by means of a prospectus supplement
and related prospectus, copies of which may be obtained by
contacting Goldman Sachs & Co. LLC, Prospectus Department,
200 West Street, New York, NY 10282, by telephone at
1-866-471-2526, by facsimile at 212-902-9316 or by email
at prospectus-ny@ny.email.gs.com; or J.P. Morgan Securities
LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, New York 11717, by telephone at (866) 803-9204, or by
email at prospectus-eq_fi@jpmchase.com; or Barclays Capital Inc.,
c/o Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, New York 11717; barclaysprospectus@broadridge.com (phone
888-603-5847).
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy any securities nor shall there be
any sale of these securities in any state in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of such state.
About Alnylam Pharmaceuticals
Alnylam (Nasdaq: ALNY) is leading the translation of RNA
interference (RNAi) into a whole new class of innovative medicines
with the potential to transform the lives of people afflicted with
rare genetic, cardio-metabolic, and hepatic infectious diseases.
Based on Nobel Prize-winning science, RNAi therapeutics represent a
powerful, clinically validated approach for the treatment of a wide
range of severe and debilitating diseases. Founded in 2002, Alnylam
is delivering on a bold vision to turn scientific possibility into
reality, with a robust discovery platform and deep pipeline of
investigational medicines, including four product candidates that
are in late-stage development. Looking forward, Alnylam will
continue to execute on its “Alnylam 2020” strategy of building a
multi-product, commercial-stage biopharmaceutical company with a
sustainable pipeline of RNAi-based medicines to address the needs
of patients who have limited or inadequate treatment options.
Alnylam employs over 600 people in the U.S. and Europe and is
headquartered in Cambridge, MA.
Alnylam Forward-Looking Statements
Statements in this release concerning Alnylam’s future
expectations, plans and prospects, including, without limitation,
statements about Alnylam’s public offering, intended use of
proceeds and Alnylam’s expectations regarding future company
achievements, constitute forward-looking statements for the
purposes of the safe harbor provisions under The Private Securities
Litigation Reform Act of 1995. Actual results and future plans may
differ materially from those indicated by these forward-looking
statements as a result of various important factors, including,
without limitation, risks related to fluctuations in our stock
price, those associated with market conditions, as well as those
risks more fully discussed in the “Risk Factors” filed with
Alnylam’s most recent Quarterly Report on Form 10-Q filed with
the SEC and in other filings that Alnylam makes with
the SEC. You should not place undue reliance on these
forward-looking statements. In addition, any forward-looking
statements represent Alnylam’s views only as of today and should
not be relied upon as representing its views as of any subsequent
date. Alnylam explicitly disclaims any obligation, except to the
extent required by law, to update any forward-looking
statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171116006323/en/
Alnylam Pharmaceuticals, Inc.Investors and MediaChristine
Regan Lindenboom, 617-682-4340orInvestorsJosh Brodsky,
617-551-8276orMichael Mason, 617-551-8327
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Sep 2023 to Sep 2024